Company research / BBIO
BridgeBio Pharma, Inc. (BBIO)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
For the year ended 2025-12-31, BridgeBio Pharma, Inc. reported revenue of $502.08M. Revenue grew 126.3% from the prior annual period.
Key ratios (year ended 2025-12-31)
-104.2%
Operating margin
-146.0%
Net margin
126.3%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.